Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)

Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

Right on the heels of back-to-back break­through ther­a­py des­ig­na­tions for its lead RSV vac­cine, Pfiz­er is wa­ger­ing up to $525 mil­lion on a biotech buy­out that in­jects new RSV as­sets in­to its pipeline.

Pfiz­er is snap­ping up Re­Vi­ral af­ter in­spect­ing mid-stage da­ta for sisuna­tovir, an oral drug that blocks the fu­sion of RSV with host cells. And there’s more.

In their state­ment, Pfiz­er not­ed:

Sisuna­tovir sig­nif­i­cant­ly re­duced vi­ral load in a phase 2 RSV hu­man chal­lenge study in healthy adults and is cur­rent­ly in Phase 2 clin­i­cal de­vel­op­ment in in­fants. The de­vel­op­ment pro­gram for sisuna­tovir is ex­pect­ed to con­tin­ue in both adult and pe­di­atric pop­u­la­tions. A sec­ond pro­gram is fo­cused on the in­hi­bi­tion of RSV repli­ca­tion tar­get­ing the vi­ral N pro­tein. The lead can­di­date in this pro­gram is cur­rent­ly in Phase 1 clin­i­cal de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.